Prothena (PRTA) to Release Earnings on Thursday

Prothena (NASDAQ:PRTA) is anticipated to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Prothena to post earnings of ($0.31) per share and revenue of $0.8090 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.67 million. Prothena had a negative return on equity of 65.89% and a negative net margin of 2,520.57%. On average, analysts expect Prothena to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Prothena Trading Up 0.7%

NASDAQ PRTA traded up $0.08 during trading on Wednesday, hitting $11.27. 62,163 shares of the company’s stock were exchanged, compared to its average volume of 485,042. The company has a market cap of $606.66 million, a PE ratio of -2.48, a P/E/G ratio of 0.38 and a beta of -0.23. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $11.69. The stock’s 50 day moving average price is $9.85 and its two-hundred day moving average price is $9.80.

Wall Street Analyst Weigh In

Several brokerages have commented on PRTA. Weiss Ratings downgraded Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. Citigroup restated a “market outperform” rating on shares of Prothena in a report on Friday, March 13th. Royal Bank Of Canada boosted their price target on Prothena from $11.00 to $12.00 and gave the stock a “sector perform” rating in a report on Friday, February 20th. Finally, Stifel Nicolaus set a $19.00 price target on Prothena in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.67.

Hedge Funds Weigh In On Prothena

Institutional investors have recently added to or reduced their stakes in the business. PDT Partners LLC acquired a new position in Prothena in the fourth quarter valued at approximately $108,000. DRW Securities LLC acquired a new position in Prothena in the fourth quarter valued at approximately $114,000. Brooklyn Investment Group lifted its stake in Prothena by 13.1% in the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,456 shares during the period. Tower Research Capital LLC TRC lifted its stake in Prothena by 571.0% in the second quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,815 shares during the period. Finally, Entropy Technologies LP acquired a new position in Prothena in the fourth quarter valued at approximately $161,000. 97.08% of the stock is owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.